Lung Cancer

Cigarette smoking is the leading cause of preventable death in the United States, accounting for approximately 443,000 deaths, or 1 of every 5 deaths each year.

Dr.Ken Yoneda from UC Davis Cancer Center Discusses Integrating the Pulmonologist into Multidisciplinary Practice

Dr. Jeffrey Bradley from Washington University School of Medicine Discusses Key Lung Cancer Topics

Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene

Dr. Giorgio V. Scagliotti from the University of Turin Discusses the Future of Lung Cancer Therapy

Dr. Paul Baas from the Netherlands Cancer Institute on the Standard of Care for Mesothelioma Patients

Dr. Ken Yoneda from the UC Davis Cancer Center Describes the Clinical Care Pulmonologist

Dr. Tianhong Li from UC Davis Cancer Center Discusses the PROFILE Crizotinib Clinical Trials

Dr. Giorgio V. Scagliotti from the University of Turin Discusses Personalizing Care With Pemetrexed

While smoking and lung cancer have always been closely linked, recent advances in research have begun to unravel the genetic code behind the disease.

Dr. Tianhong (Tina) Li from UC Davic Cancer Center Discusses ALK Gene Mutation Tests

On Friday, August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non–small cell lung cancer (NSCLC).

Dr. Ken Y. Yoneda from UC Davis Cancer Center on Advances in the Diagnosis of Lung Cancer

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Dr. Karen Reckamp from the City of Hope Cancer Center Discusses the Use of Hsp90 Inhibitors

Dr. Ken Yoneda from UC Davis Cancer Center Discusses Bronchoscopy Tools and Procedures

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials

Dr. Ken Yoneda from UC Davis Cancer Center Discusses the Role of the Pulmonologist

Dr. Karen Reckamp from City of Hope Cancer Center Describes the Use of Heat Shock Proteins

Dr. Karen Reckamp from City of Hope Cancer center Discusses Heat Shock Proteins in Lung Cancer

Dr. Roy S. Herbst from Yale Comprehensive Cancer Center on Themes From the 2011 Lung Cancer Congress

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Available Targeted Therapies

Dr. Roy S. Herbst from Yale comprehensive cancer center on the International Lung Cancer Congress

Dr. Roy Herbst from the Yale Comprehensive Cancer Center on Screening Studies at the Upcoming Lung Cancer Congress

A new study found that biopsies of lung nodules found during a CT scan may be unnecessary and dangerous.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Patient Acceptance of Mutation Testing

PFS improved significantly in patients with EGFR-mutated advanced NSCLC treated first line with erlotinib versus platinum-based chemotherapy.

Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on How the Institutes in the mutlicenter study examining driver mutations Worked Together